Disease control: 82% demonstrated >50% reduction of injected tumours; 43% in non-injected tumoursImmune response: 67% demonstrated increased CD8+ TILs; demonstrated increased systemic proliferating CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.